Circulating tumor DNA assays in clinical cancer research

MR Ossandon, L Agrawal, EJ Bernhard… - JNCI: Journal of the …, 2018 - academic.oup.com
The importance of circulating free DNA (cfDNA) in cancer clinical research was recognized
in 1994 when a mutated RAS gene fragment was detected in a patient’s blood sample. Up to …

Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo

M Oberst, J Anders, B Xie, B Singh, M Ossandon… - The American journal of …, 2001 - Elsevier
Matriptase and its cognate, Kunitz-type serine protease inhibitor, HAI-1, comprise a newly
characterized extracellular matrix-degrading protease system that may function as an …

Low-cost technologies for medical diagnostics in low-resource settings

J Balsam, M Ossandon, HA Bruck… - Expert opinion on …, 2013 - Taylor & Francis
Introduction: Medical diagnostics is a critical element of effective medical treatment. However,
many modern and emerging diagnostic technologies are not affordable or compatible with …

[HTML][HTML] The making of a PreCancer Atlas: promises, challenges, and opportunities

…, S Lockett, T Misteli, S Nelson, H Odeh, M Ossandon… - Trends in Cancer, 2018 - cell.com
Many cancers evolve from benign precancerous lesions and have a natural history of
progression that provides a window of opportunity for intervention. The biological mechanisms …

The role of affordable, point-of-care technologies for cancer care in low-and middle-income countries: A review and commentary

…, P Tandon, R Divi, MR Ossandon… - IEEE journal of …, 2017 - ieeexplore.ieee.org
… Divi is with the National Cancer Institute, Rockville, MD 20850 USA (e-mail: divir@dc37a.nci.nih.gov)
M. Ossandon is with the National Cancer Institute, Rockville, MD 20850 USA (e-…

[HTML][HTML] Angiogenin: a marker for preterm delivery in midtrimester amniotic fluid

…, DM Sherer, JC Pezzullo, M Ossandon… - American journal of …, 1997 - Elsevier
OBJECTIVE: Neovascularization is a response of tissue to ischemic damage. Placental
ischemia is thought to underlie a significant portion of preterm deliveries. Our objective was to …

Lab-on-a-chip for botulinum neurotoxin a (BoNT-A) activity analysis

S Sun, M Ossandon, Y Kostov, A Rasooly - Lab on a Chip, 2009 - pubs.rsc.org
A Lab-on-a-chip (LOC) was designed, fabricated and tested for the in vitrodetection of
botulinum neurotoxin serotype A (BoNT-A) activity using an assay that measures cleavage of a …

Lensless CCD-based fluorometer using a micromachined optical Söller collimator

J Balsam, M Ossandon, Y Kostov, HA Bruck… - Lab on a Chip, 2011 - pubs.rsc.org
In this paper, we describe a simple charge-coupled device (CCD) based lensless fluorometer
with sensitivity in the range of current ELISA plate readers. In our lensfree fluorometer, a …

The National Institutes of Health Affordable Cancer Technologies program: Improving access to resource-appropriate technologies for cancer detection, diagnosis …

…, P Tandon, BS Sorg, MR Ossandon… - IEEE journal of …, 2016 - ieeexplore.ieee.org
… The m-health revolution has had a profound effect on the global community, as many of
the lowest-resource populations still have widespread access to mobile devices. While m-health …

Are the cytokines interleukin-6 and angiogenin stable in frozen amniotic fluid?

CY Spong, A Ghidini, M Ossandon, CN Walker… - American journal of …, 1998 - Elsevier
OBJECTIVE: To determine the stability of cytokines in frozen stored amniotic fluid samples,
we measured angiogenin, a potent inducer of neovascularization and interleukin-6, an …